Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2019-04-01 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma à l’AACR 2019 : nouvelles données sur la prochaine génération d’immunothérapies des cancers
Investor Presentation Classification · 92% confidence The document is a press release dated April 1, 2019, announcing the presentation of new preclinical data on Innate Pharma's immunotherapies at the AACR 2019 conference. It details scientific findings (IPH5201, IPH5301, NKCE technology), mentions collaborations, and provides forward-looking statements and contact information typical of corporate news releases regarding scientific progress. This content strongly aligns with an Earnings Release (ER) or a general corporate update, but since it focuses purely on scientific/pipeline updates rather than period financial results (like revenue/net income), it is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a corporate announcement. Given the options, this is a detailed scientific update intended for investors and the scientific community, often released around major conferences. However, it is structured as a formal press release announcing scientific progress, which is often categorized under Earnings Release (ER) if it's a major update, or sometimes as Regulatory Filings (RNS) if it's not a standard financial report. Since it is a detailed announcement of scientific progress and pipeline updates, it fits the scope of an Investor Presentation (IP) content-wise, but the format is a press release. Because it is not a formal financial report (10-K, IR, ER), and it details specific scientific data and pipeline progress, it is closest to an Investor Presentation (IP) in substance, or potentially an Earnings Release (ER) if the company uses this format for major pipeline news. Given the focus on scientific data presentation at a conference, 'Investor Presentation' (IP) is a strong fit for the *content*, but 'Earnings Release' (ER) is often used for major corporate news announcements. Since it is not a transcript (CT) or a formal financial report (10-K/IR), and it is a detailed announcement, I will lean towards ER as the most common classification for major corporate news releases, although IP is plausible for the content type. Re-evaluating the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document does not contain financial highlights. IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document focuses heavily on strategy and pipeline data. Given the lack of financial highlights, IP is a better fit than ER. It is a detailed announcement of scientific progress, which is a key part of investor strategy communication.
2019-04-01 French
Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
Regulatory Filings Classification · 95% confidence The document is a press release dated April 1, 2019, detailing scientific data presented by Innate Pharma's CSO at the American Association for Cancer Research (AACR) 2019 Annual Meeting. It highlights preclinical data on specific drug candidates (IPH5201, IPH5301) and the company's NKCE technology. This content is typical of an announcement summarizing scientific progress or research findings, often released around a major conference. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a management discussion (MDA). Since it is a press release announcing scientific updates and progress, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate/scientific update, although it is more specific than a generic RNS. Given the options, and since it is not a formal financial report, an earnings release, or a presentation attachment, RNS serves as the most appropriate catch-all for significant, non-financial regulatory/corporate news releases that don't fit other specific categories like DIV, CAP, or MANG. However, because it is a detailed scientific update, it is often classified as an Investor Presentation (IP) if it were the slides themselves, but as a press release *about* the presentation, RNS is the best fit among the provided codes for general corporate news.
2019-04-01 English
Resultats annuels 2018 : accord majeur avec AstraZeneca appuyant la transition vers une societe de biotechnologies integree et donnees prometteuses pour les programmes principaux
Earnings Release Classification · 99% confidence The document is titled "RESULTATS ANNUELS 2018" (Annual Results 2018) and explicitly states: "Innate Pharma... annonce aujourd'hui ses résultats financiers consolidés au 31 décembre 2018." It contains detailed financial tables comparing 2018 results to 2017, including income statements, balance sheet items, and earnings per share. This content structure and explicit reference to annual consolidated financial results strongly indicate a comprehensive annual financial report. Although it is presented as a press release announcing the results, the document itself contains the full financial statements and detailed analysis typical of an Annual Report (10-K equivalent in structure, though likely filed under a local jurisdiction's equivalent or as a press release accompanying the formal filing). Given the depth of the financial data provided (tables, detailed commentary on revenue, expenses, and balance sheet items for the full year), it is classified as the Annual Report content rather than just an Earnings Release (ER) or Report Publication Announcement (RPA). FY 2018
2019-03-20 French
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Regulatory Filings
2019-03-20 English
Innate Pharma: Jennifer Butler nommée VP exécutif, DG de la filiale américaine
Board/Management Information Classification · 99% confidence The document is a press release dated March 12, 2019, announcing the appointment of Jennifer Butler as Executive Vice President and General Manager of the US subsidiary, along with other key management hires (Hélène Arditti and Guillaume Gimonet). This content directly relates to changes in the company's senior management team and board structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (DEF 14A/PSI).
2019-03-12 French
Innate Pharma: Jennifer Butler appointed as Executive VP, General Manager, US
Board/Management Information Classification · 99% confidence The document is a press release titled "INNATE PHARMA ANNOUNCES THE APPOINTMENT OF JENNIFER BUTLER AS EXECUTIVE VICE PRESIDENT, GENERAL MANAGER, US". It details changes in senior management, specifically the appointment of a new EVP/GM and other senior commercial roles (Hélène Arditti and Guillaume Gimonet). This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2019-03-12 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.